Multicenter prospective study of concordance between embryonic cell-free DNA and trophectoderm biopsies from 1301 human blastocysts.


Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
11 2020
Historique:
received: 18 02 2020
revised: 21 04 2020
accepted: 28 04 2020
pubmed: 30 5 2020
medline: 1 12 2020
entrez: 30 5 2020
Statut: ppublish

Résumé

The recent identification of embryonic cell-free DNA in spent blastocyst media has opened a new era of possibilities for noninvasive embryo aneuploidy testing in assisted reproductive technologies. Yet, previous studies assessing a limited number of embryos reported variable concordance between embryonic cell-free DNA and trophectoderm biopsies, thus questioning the validity of this approach. This study aimed to evaluate the concordance and reproducibility of testing embryonic cell-free DNA vs trophectoderm DNA obtained from the same embryo in a large sample of human blastocysts and to assess the contribution of the inner cell mass and trophectoderm to embryonic cell-free DNA released to the culture media. This is an interim analysis of a prospective, observational study among 8 in vitro fertilization centers in 4 continents to assess consistency between noninvasive embryo aneuploidy testing of embryonic cell-free DNA and conventional trophectoderm biopsy. The analysis included 1301 day-6/7 blastocysts obtained in 406 in vitro fertilization cycles from 371 patients aged 20-44 years undergoing preimplantation genetic testing for aneuploidy. Fresh oocytes underwent intracytoplasmic sperm injection or in vitro fertilization. No previous assisted hatching or vitrification was allowed before media collection. Individual spent blastocyst medium was collected from embryos cultured at least 40 hours from day 4. After media collection, conventional preimplantation genetic testing for aneuploidy, comprising trophectoderm biopsy and blastocyst vitrification, was performed. Embryonic cell-free DNA was analyzed blindly after embryo transfer. Inner cell mass and trophectoderm biopsies were also performed in a subset of 81 aneuploid blastocysts donated for research. Embryonic cell-free DNA analyses were 78.2% (866/1108) concordant with the corresponding trophectoderm biopsies. No significant differences were detected among centers ranging from 72.5% to 86.3%. Concordance rates exceeded 86% when all defined steps in the culture laboratory were controlled to minimize the impact of maternal and operator contamination. Sensitivity per center ranged from 76.5% to 91.3% and specificity from 64.7% to 93.3%. The false-negative rate was 8.3% (92/1108), and false-positive rate was 12.4% (137/1108). The 2 fertilization techniques provided similar sensitivity (80.9% vs 87.9%) and specificity (78.6% vs 69.9%). Multivariate analysis did not reveal any bias from patient clinical background, ovarian stimulation protocols, culture conditions, or embryo quality on testing accuracy of concordance. Moreover, concordances of embryonic cell-free DNA with trophectoderm and inner cell mass suggest that the embryonic cell-free DNA originates from both compartments of the human embryo. Noninvasive analysis of embryonic cell-free DNA in spent blastocyst culture media demonstrates high concordance with trophectoderm biopsy results in this large multicenter series. A noninvasive approach for prioritizing embryo euploidy offers important advantages such as avoiding invasive embryo biopsy and decreased cost, potentially increasing accessibility for a wider patient population.

Sections du résumé

BACKGROUND
The recent identification of embryonic cell-free DNA in spent blastocyst media has opened a new era of possibilities for noninvasive embryo aneuploidy testing in assisted reproductive technologies. Yet, previous studies assessing a limited number of embryos reported variable concordance between embryonic cell-free DNA and trophectoderm biopsies, thus questioning the validity of this approach.
OBJECTIVE
This study aimed to evaluate the concordance and reproducibility of testing embryonic cell-free DNA vs trophectoderm DNA obtained from the same embryo in a large sample of human blastocysts and to assess the contribution of the inner cell mass and trophectoderm to embryonic cell-free DNA released to the culture media.
STUDY DESIGN
This is an interim analysis of a prospective, observational study among 8 in vitro fertilization centers in 4 continents to assess consistency between noninvasive embryo aneuploidy testing of embryonic cell-free DNA and conventional trophectoderm biopsy. The analysis included 1301 day-6/7 blastocysts obtained in 406 in vitro fertilization cycles from 371 patients aged 20-44 years undergoing preimplantation genetic testing for aneuploidy. Fresh oocytes underwent intracytoplasmic sperm injection or in vitro fertilization. No previous assisted hatching or vitrification was allowed before media collection. Individual spent blastocyst medium was collected from embryos cultured at least 40 hours from day 4. After media collection, conventional preimplantation genetic testing for aneuploidy, comprising trophectoderm biopsy and blastocyst vitrification, was performed. Embryonic cell-free DNA was analyzed blindly after embryo transfer. Inner cell mass and trophectoderm biopsies were also performed in a subset of 81 aneuploid blastocysts donated for research.
RESULTS
Embryonic cell-free DNA analyses were 78.2% (866/1108) concordant with the corresponding trophectoderm biopsies. No significant differences were detected among centers ranging from 72.5% to 86.3%. Concordance rates exceeded 86% when all defined steps in the culture laboratory were controlled to minimize the impact of maternal and operator contamination. Sensitivity per center ranged from 76.5% to 91.3% and specificity from 64.7% to 93.3%. The false-negative rate was 8.3% (92/1108), and false-positive rate was 12.4% (137/1108). The 2 fertilization techniques provided similar sensitivity (80.9% vs 87.9%) and specificity (78.6% vs 69.9%). Multivariate analysis did not reveal any bias from patient clinical background, ovarian stimulation protocols, culture conditions, or embryo quality on testing accuracy of concordance. Moreover, concordances of embryonic cell-free DNA with trophectoderm and inner cell mass suggest that the embryonic cell-free DNA originates from both compartments of the human embryo.
CONCLUSION
Noninvasive analysis of embryonic cell-free DNA in spent blastocyst culture media demonstrates high concordance with trophectoderm biopsy results in this large multicenter series. A noninvasive approach for prioritizing embryo euploidy offers important advantages such as avoiding invasive embryo biopsy and decreased cost, potentially increasing accessibility for a wider patient population.

Identifiants

pubmed: 32470458
pii: S0002-9378(20)30520-2
doi: 10.1016/j.ajog.2020.04.035
pii:
doi:

Substances chimiques

Cell-Free Nucleic Acids 0
Culture Media 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

751.e1-751.e13

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Carmen Rubio (C)

R&D Department, Igenomix, Valencia, Spain. Electronic address: carmen.rubio@igenomix.com.

Luis Navarro-Sánchez (L)

R&D Department, Igenomix, Valencia, Spain.

Carmen M García-Pascual (CM)

R&D Department, Igenomix, Valencia, Spain.

Olcay Ocali (O)

IVF Laboratory, Boston IVF Fertility Clinic, Boston, MA.

Danilo Cimadomo (D)

GENERA Center for Reproductive Medicine, Clinica Valle Giulia, Rome, Italy.

William Venier (W)

IVF Laboratory, San Diego Fertility Center, San Diego, CA.

Gerardo Barroso (G)

IVF Clinical Department, Escuela Superior de Medicina Instituto Politécnico Nacional y Centro de Reproducción Arcos S.C. NASCERE, CDMX, Mexico.

Laura Kopcow (L)

Department of Reproductive Genetics, Pregna Medicina Reproductiva, Buenos Aires, Argentina.

Mustafa Bahçeci (M)

Clinical Department, Bahçeci Fertility, Istanbul, Turkey.

Marcos Iuri Roos Kulmann (MIR)

Embryology Department, Nilo Frantz Reproductive Medicine, Porto Alegre, Brazil.

Lourdes López (L)

IVF Laboratory, ProcreaTec International Fertility Clinic, Madrid, Spain.

Emilio De la Fuente (E)

Clinical Studies Department, Igenomix, Valencia, Spain.

Roser Navarro (R)

Bioinformatics Department, Igenomix, Valencia, Spain.

Diana Valbuena (D)

Medical Department, Igenomix, Valencia, Spain.

Denny Sakkas (D)

IVF Laboratory, Boston IVF Fertility Clinic, Boston, MA.

Laura Rienzi (L)

GENERA Center for Reproductive Medicine, Clinica Valle Giulia, Rome, Italy.

Carlos Simón (C)

Igenomix Foundation/Instituto de Investigación Sanitaria Hospital Clínico (INCLIVA) and Department of Pediatrics, Obstetrics and Gynecology, Universidad de Valencia, Valencia, Spain, and Department of Obstetrics and Gynecology, BIDMC, Harvard University, Cambridge, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH